U.S. Physical Therapy (USPH)
(Delayed Data from NYSE)
$106.72 USD
+0.47 (0.44%)
Updated May 17, 2024 04:00 PM ET
After-Market: $106.48 -0.24 (-0.22%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
USPH 106.72 +0.47(0.44%)
Will USPH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for USPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for USPH
U.S. Physical Therapy (USPH) Misses Q1 Earnings Estimates
The Pennant Group, Inc. (PNTG) Tops Q1 Earnings and Revenue Estimates
USPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
ADUS or USPH: Which Is the Better Value Stock Right Now?
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS vs. USPH: Which Stock Should Value Investors Buy Now?
Other News for USPH
Insider Sale: Director Edward Kuntz Sells 2,500 Shares of US Physical Therapy Inc (USPH)
U.S. Physical Therapy to Present at the Bank of America Securities Healthcare Conference 2024
Analysts’ Top Healthcare Picks: US Physical Therapy (USPH), Exact Sciences (EXAS)
Buy Rating for US Physical Therapy: Strong Performance and Positive Growth Outlook
U.S. Physical Therapy Executives Present at Healthcare Conference